AMPLATZER PICCOLO™ OCCLUDER

CLOSES EARLY PDAs. FILLS LOVING HEARTS.

PROVEN PDA CLOSURE FOR PATIENTS 700G AND UP.

Information contained herein for **DISTRIBUTION** in Australia and New Zealand only.




A NEW LEVEL OF VERSATILITY AND PROVEN SAFETY FOR THE YOUNGEST INFANTS AND UP.

CLINICALLY PROVEN OUTCOMES.

The safety and efficacy of the Amplatzer PiccoloTM Occluder in patients weighing \geq 700 grams was studied in a 50 patient pivotal trial and 150 additional patients under a continued access protocol. When combined, the study enrolled a total of 200 patients. At the time of the procedure, 100 patients weighed \leq 2 kg and the other 100 patients weighed >2 kg.


STUDY HIGHLIGHTS



TOTAL NUMBER OF PATIENTS: 200	≤ 2 kg (N=1
	DEMOGR
Age, Months	
Mean ± SD	1.25 ± 0.60
Range	(0.30 - 3.15)
Weight (kg)	
Mean ± SD	1.25 ± 0.35
Range	(0.70 - 2.00)
PDA	CHARACTERIS
Minimal PDA Diameter (mm)	
Mean ± SD	2.8 ± 0.7
Range	(1.4 - 4.0)
PDA Length (mm)	
Mean ± SD	10.6 ± 2.2
Range	(5.3 - 19.2)
PF	ROCEDURE CHA
Implant Success (%)	99.0% (99/10
Fluoroscopy Time (min)	
Mean ± SD	10.5 ± 12.4
Range	(3 - 103)
Anterograde Implant	100.0% (99/9
Femoral Arterial Access	2.0% (2/100)
In NICU at time of baseline assessment	100.0% (100
	OUTCO
Major complications rate through 180 days (%)**	4.2% (4/96)
Effective closure at 6 months (%)	100% (89/89

BUILT ON THE EXTENSIVE AMPLATZER™ LEGACY OF SAFETY AND EFFICACY

- Pioneered transcatheter occlusion
- Over 1.25 million devices implanted worldwide¹
- More than 20 years of clinical experience



0% for patients >2kg

> 2 kg (N=100) Total (N=200) 00) APHICS 26.58 ± 44.32 3.92 ± 33.74 (0.49 - 216.80) (0.30 - 216.80) 11.25 ± 13.52 6.25 ± 10.77 (2.02-68.50)(0.70 - 68.50) TICS (by angiography) 2.6 ± 0.7 2.4 ± 0.7 (1.0 - 4.0)(1.0 - 4.0) 10.1 ± 3.4 104 + 29(4.1 - 20.0) (4.1 - 20.0) ARACTERISTICS 92% (92/100) 95.5% (191/200) (00) 10.1 ± 7.0 10.3 ± 10.0 (3 - 43) (3 - 103) 73.9% (68/92) 87.4% (167/191) (99) 48.0% (48/100) 25.0% (50/200) 32.0% (32/100) 66.0% (132/200))/100)OMES 2.1% (4/194) 0% (0/98) 98.8% (83/84) 99.4% (172/173)

ADVANCING A PROVEN PLATFORM FOR PREDICTABLE RESULTS.

As the only PDA closure solution indicated for premature infants (\geq 700g and \geq 3 days old) and proven to deliver safe and effective closure, Amplatzer Piccolo™ Occluder offers new opportunities to care for a wider range of patients than ever before.

RELIABILITY BY DESIGN.


ENGINEERED FOR STRUCTURE AND STRENGTH

Occludes ducts while minimizing protrusion into surrounding vasculature

SMOOTH DELIVERY IN EVEN THE MOST CHALLENGING MORPHOLOGIES.

PREDICTABLE PLACEMENT

Disc size and shape designed for predictable positioning in the duct



PROCEDURAL FLEXIBILITY

Symmetrical design offers procedural flexibility to choose an anterograde (venous) or retrograde (arterial) approach. For infants \leq 2kg, a venous approach is recommended.

TIGHTLY WOVEN SINGLE-LAYER MESH

Designed to minimize residual shunt immediately after placement

INTAGLIO WIRE TREATMENT

Designed to reduce nickel leaching



DELIVERABLE IN 4 FRENCH SYSTEM

4 F catheter facilitates delivery in small vasculatures



THE RIGHT CHOICE FOR A WIDE RANGE OF ANATOMIES.

The versatile design and predictable performance of the Amplatzer Piccolo[™] Occluder make it ideal for a variety of morphologies. From "conical" ductus to "fetal type" ductus, the Piccolo device has you covered.

PDA TYPE DESCRIPTION ²	PDA ²	DEVICE CLOSURE ²	≤2KG³	> 2KG ³
TYPE A: "Conical" ductus, with well defined aortic ampulla and constricted pulmonary artery end.			6%	43%
TYPE B: "Window" ductus, with short length, slightly constricted aortic end and wide pulmonary artery end.		-	1%	2%
TYPE C: "Tubular" ductus, without any constrictions at the aortic end or the pulmonary artery end.		ALE	16%	12%
TYPE D: "Saccular" ductus, with constricted aortic end and pulmonary artery end with a wide center.		+	0%	5%
TYPE E: "Elongated" ductus, which is narrow with a constricted pulmonary artery end.	S	N	5%	13%
TYPE F: "Fetal Type" ductus, found exclusively in children born prematurely and is long, wide and tortuous.	(3)	A	70%	21%

Information contained herein for **DISTRIBUTION** n Australia and New Zealand only.

Images reproduced with permission of Dr. Shyam Sathanandam, Le Bonheur Children's Hospital.

EXPERT SUPPORT AT EVERY TURN.

CLINICAL CASE SUPPORT

- Experienced field personnel
- Over two decades of excellence

CLINICAL TRAINING PROGRAMS

- Training centers and online courses
- Fellows programs

AMPLATZER PICCOLO™ OCCLUDER

Device Specifications


SIZING AND DEVICE SELECTION							
Model/Reorder Number	Waist Diameter (mm) [A]	Length between discs (mm) [B]	Disc Diameter (mm) [C]	Recommended Sheath Size			
9-PDAP-03-02-L	3 mm	2 mm	4.00	4 F; 90° Curve			
9-PDAP-03-04-L	3 mm	4 mm	4.00	4 F; 90° Curve			
9-PDAP-03-06-L	3 mm	6 mm	4.00	4 F; 90° Curve			
9-PDAP-04-02-L	4 mm	2 mm	5.25	4 F; 90° Curve			
9-PDAP-04-04-L	4 mm	4 mm	5.25	4 F; 90° Curve			
9-PDAP-04-06-L	4 mm	6 mm	5.25	4 F; 90° Curve			
9-PDAP-05-02-L	5 mm	2 mm	6.50	4 F; 90° Curve			
9-PDAP-05-04-L	5 mm	4 mm	6.50	4 F; 90° Curve			
9-PDAP-05-06-L	5 mm	6 mm	6.50	4 F; 90° Curve			

T1 Dimensions

[A] Waist diameter

[B] Length between retention discs

[C] Retention disc diameter



С

For more information about the Amplatzer Piccolo[™] Occluder, contact your Abbott sales representative or visit INFANTPDA.COM.

References

1. Data on file at Abbott. 2. Philip, R., Rush Waller, B., Agrawal, V., Wright, D., Arevalo, A., Zurakowski, D. and Sathanandam, S. (2016), Morphologic characterization of the patent ductus arteriosus in the premature infant and the choice of transcatheter occlusion device. *Cathet. Cardiovasc. Intervent.*, 87: 310–317. 3. Sathanandam SK, Gutfinger D, O'Brien L, et al. Amplatzer Piccolo Occluder clinical trial for percutaneous closure of the patent ductus arteriosus in patients ≥700 grams. *Catheter Cardiovasc Interv.* 2020;1–11.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Information contained herein for DISTRIBUTION in Australia and New Zealand ONLY.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Photo(s) on file at Abbott.

Abbott Medical Australia Pty Ltd, 299 Lane Cove Road, Macquarie Park, NSW 2113, Ph: 1800 839 259. Abbott Medical New Zealand Ltd, 4 Pacific Rise, Mount Wellington, Auckland 1060, Tel: 0800 756 269.



TM Indicates a trademark of the Abbott Group of Companies

 \odot 2022 Abbott. All rights reserved. MAT-2212484 v1.0 | Item approved for use in ANZ only.